Overview

Careers

We have a pipeline of novel, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders

Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. The company’s clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein-cholesterol (LDL-C), patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. VK2735 is currently being evaluated in a Phase 1 clinical trial. In the rare disease space, the company is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD.

Development Programs Indication Preclinical Phase 1 Phase 2 Phase 3 Status
VK2809 (TRβ Agonist) NASH
60%
Phase 2b VOYAGE trial ongoing
VK2735 (Dual GLP-1/GIP agonist) Metabolic disorders
35%
Phase 1 ongoing
VK0214 (TRβ Agonist) X-ALD
35%
Phase 1b ongoing
Other Programs Indication Preclinical Phase 1 Phase 2 Phase 3 Status
VK5211 (SARM) Hip fracture, muscle wasting
60%
Phase 2 completed
VK0612 (FBPase inhibitor) Type 2 Diabetes
60%
Phase 2a completed
VK1430 (DGAT-1 inhibitor) Hypertriglyceridemia, NASH
23%
Preclinical